Polycythemia Vera Drug Market: A Study of Besremi, Jakafi, and Rusfertide

March 28, 2023

Polycythemia Vera Treatment Landscape

FDA-approved medication Jakafi (ruxolitinib), created by Incyte, is used to treat Polycythemia Vera. Jakafi is a JAK1/JAK2 inhibitor that lessens the overactive JAK1 and JAK2 signalling that is connected to the symptoms of polycythemia vera. The patent for Jakafi expires in 2027, but numerous businesses have already submitted generic applications. The introduction of generics could be delayed, though, as a result of legal disputes.

PharmaEssentia’s new entrant, entry into NCCN guidelines, insights on pricing, and launches

PharmaEssentia's Besremi (Ropeginterferon alfa-2b) is a brand-new medication for Polycythemia Vera. It works differently than Jakafi and is administered subcutaneously. Besremi is an interferon alpha-2b derivative that controls the immune system and bone marrow, which can aid in reducing Polycythemia Vera's excessive production of blood cells. Besremi obtained FDA approval in the US in 2021 after being approved in the EU in 2020. Also, it is mentioned in the National Comprehensive Cancer Network's (NCCN) recommendations for Polycythemia Vera treatment. Besremi's introduction is anticipated for 2021, and the price has not yet been disclosed.

Protagonist therapeutics’ Rusfertide: Uncertainty in uptake even with promising results?

Rusfertide (PTG-300) is an investigational drug developed by Protagonist Therapeutics for the treatment of Polycythemia Vera. Rusfertide is a hepcidin mimetic that regulates iron metabolism and controls erythropoiesis, which could help treat anemia in Polycythemia Vera. Rusfertide has shown promising results in clinical trials, and Protagonist has plans for its commercialization. However, the drug recently faced a setback as the FDA withdrew its Breakthrough Therapy Designation (BTD) due to concerns about the design of ongoing clinical trials. The uncertainty about Rusfertide’s approval could affect its uptake in the Polycythemia Vera market.

In conclusion, the approval of novel medications like Besremi and research-stage medications like Rusfertide has resulted in some substantial changes in the Polycythemia Vera market in recent years. The introduction of generic Jakafi medications could be delayed by legal issues. Besremi's launch is anticipated to occur soon, although its price has not yet been made public. The market acceptance of Rusfertide for Polycythemia Vera may be hampered by the uncertainties surrounding its approval. Nonetheless, the market for Polycythemia Vera is anticipated to expand in the upcoming years due to the availability of novel medications and cutting-edge treatments.

Related Reports

B Cell Chronic Lymphocytic Leukemia Market

DelveInsight's "B Cell Chronic Lymphocytic Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Chronic Lymphocytic Leukemia, historical and forecasted epidemiology as well as the B Cell Chronic Lymphocytic Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

B-Cell Lymphomas Market

DelveInsight's "B-Cell Lymphomas Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Lymphomas, historical and forecasted epidemiology as well as the B-Cell Lymphomas market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Behcet’s Syndrome Market

DelveInsight’s “Behcet’s Syndrome Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Behcet’s syndrome in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom.

Neoantigen-based Personalized Cancer therapeutic Vaccines

DelveInsight’s “Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035” report delivers an in-depth understanding of the Neoantigen based Personalized Cancer therapeutic Vaccines and the Neoantigen-based personalized cancer therapeutic vaccines emerging market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Glioblastoma Multiforme Market

DelveInsight's "Glioblastoma Multiforme Market Insights, Epidemiology and Market Forecast– 2032" report delivers an in-depth understanding of the Glioblastoma, historical and forecasted epidemiology as well as the Glioblastoma market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Latest Reports By DelveInsight

To know more about our Consulting Services, Click here: DelveInsight Healthcare Consulting

Recent Blog’s By DelveInsight:

Click here to get the detailed information about the Polycyhemia Vera Treatment Landscape:

Search This Blog

HealthInsights